An interdisciplinary team-training protocol for robotic gynecologic surgery improves operating time and costs: analysis of a 4-year experience in a university hospital setting.
Vigo F; Egg R; Schoetzau A; Montavon C; Brezak M; Heinzelmann-Schwarz V; Kavvadias T. Journal of robotic surgery. 2022.Comparison of 2D 4K vs. 3D HD laparoscopic imaging systems using a pelvitrainer model: a randomized controlled study.
Zwimpfer TA; Wismer C; Fellmann-Fischer B; Geiger J; Schötzau A; Heinzelmann-Schwarz V. Updates in surgery. 2022.Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A. Journal for ImmunoTherapy of Cancer. 2022.Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
Fedier A; Maggi N; Tozzi A; Disler M; Coelho R; Jacob F; Heinzelmann-Schwarz V. International journal of oncology. 2022.Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways.
Cumin C; Huang YL; Rossdam C; Ruoff F; Céspedes SP; Liang CY; Lombardo FC; Coelho R; Rimmer N; Konantz M; López MN; Alam S; Schmidt A; Calabrese D; Fedier A; Vlajnic T; von Itzstein M; Templin M; Buettner FFR; Everest-Dass A; Heinzelmann-Schwarz V; Jacob F. Cell Reports. 2022.How does colpocleisis for pelvic organ prolapse in older women affect quality of life, body image, and sexuality? A critical review of the literature.
Felder L; Heinzelmann-Schwarz V; Kavvadias T. Women's health (London, England). 2022.Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
Chase DM; Marín MR; Backes F; Han S; Graybill W; Mirza MR; Pothuri B; Mangili G; O'Malley DM; Berton D; Willmott L; Baumann K; Coleman RL; Safra T; Heinzelmann-Schwarz V; Lorusso D; Karl FM; Woodward T; Monk BJ; Gonzalez-Martin A; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Gynecologic oncology. 2022.Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort.
Sarki M; Ming C; Aissaoui S; Bürki N; Caiata-Zufferey M; Erlanger TE; Graffeo-Galbiati R; Heinimann K; Heinzelmann-Schwarz V; Monnerat C; Probst-Hensch N; Rabaglio M; Zürrer-Härdi U; Chappuis PO; Katapodi MC; On Behalf Of The Cascade Consortium. Cancers. 2022.Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
McLaughlin PMJ; Klar M; Zwimpfer TA; Dutilh G; Vetter M; Marth C; du Bois A; Schade-Brittinger C; Reuss A; Bommer C; Kurzeder C; Heinzelmann-Schwarz V. BMC CANCER. 2022.Managing Cancer as a Family Disease - Feasibility, Satisfaction and Family Functioning after Short-Time Counselling for Families with Parental Cancer
Ehrbar V.; Roos S.; Denzinger A.; Bingisser M.B.; Scherer S.; Gaab J.; Vetter M.; Heinzelmann-Schwarz V.; Urech C.. Family Journal. 2022.Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V. Cell Death & Disease. 2022.Perioperative management with ferric carboxymaltose and tranexamic acid to reduce transfusion rate in gynaecological carcinoma surgery (TRANAFER-Study): study protocol for a single-blind, monocentre, randomised trial.
Amstad G; Geiger J; Werlen L; Montavon C; Heinzelmann V. BMJ Open. 2022.Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives.
Salikhanov I; Heinimann K; Chappuis P; Buerki N; Graffeo R; Heinzelmann V; Rabaglio M; Taborelli M; Wieser S; Katapodi MC. Journal of medical genetics. 2022.The double S technique to achieve aesthetic flat closure after conventional mastectomy.
Steffens D; Kappos EA; Lunger A; Schwab FD; Zehnpfennig L; Weber WP; Haug M; Heinzelmann-Schwarz V; Kurzeder C. World Journal of Surgical Oncology. 2022.The metastatic spread of breast cancer accelerates during sleep.
Diamantopoulou Z; Castro-Giner F; Schwab FD; Foerster C; Saini M; Budinjas S; Strittmatter K; Krol I; Seifert B; Heinzelmann-Schwarz V; Kurzeder C; Rochlitz C; Vetter M; Weber WP; Aceto N. Nature. 2022.Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
Sobottka B.; Nowak M.; Frei A.L.; Haberecker M.; Merki S.; Aebersold R.; Ak M.; Al-Quaddoomi F.S.; Albinus J.; Alborelli I.; Andani S.; Attinger P.-O.; Bacac M.; Baumhoer D.; Beck-Schimmer B.; Beerenwinkel N.; Beisel C.; Bernasconi L.; Bertolini A.; Bodenmiller B.; Bonilla X.; Casanova R.; Chevrier S.; Chicherova N.; D'Costa M.; Danenberg E.; Davidson N.; Draganmoch M.-A.; Engler S.; Erkens M.; Eschbach K.; Esposito C.; Fedier A.; Ferreira P.; Ficek J.; Frey B.; Goetze S.; Grob L.; Gut G.; Gunther D.; Haberecker M.; Haeuptle P.; Heinzelmann-Schwarz V.; Herter S.; Holtackers R.; Huesser T.; Irmisch A.; Jacob F.; Jacobs A.; Jaeger T.M.; Jahn K.; James A.R.; Jermann P.M.; Kahles A.; Kahraman A.; Kuebler W.; Kuipers J.; Kunze C.P.; Kurzeder C.; Lehmann K.-V.; Lugert S.; Maass G.; Manz M.G.; Markolin P.; Mena J.; Menzel U.; Metzler J.M.; Miglino N.; Milani E.S.; Muenst S.; Murri R.; Ng C.K.Y.; Nicolet S.; Pedrioli P.G.A.; Pelkmans L.; Piscuoglio S.; Prummer M.; Ritter M.; Rommel C.; Rosano-Gonzalez M.L.; Ratsch G.; Santacroce N.; del Castillo J.S.; Schlenker R.; Schwalie P.C.; Schwan S.; Schar T.; Senti G.; Singer F.; Sivapatham S.; Snijder B.; Sreedharan V.T.; Stark S.; Stekhoven D.J.; Theocharides A.P.A.; Thomas T.M.; Tolnay M.; Tosevski V.; Toussaint N.C.; Tuncel M.A.; Tusup M.; Van Drogen A.; Vetter M.; Vlajnic T.; Weber S.; Weber W.P.; Wegmann R.; Weller M.; Wendt F.; Wey N.; Wicki A.; Wildschut M.H.; Wollscheid B.; Yu S.; Ziegler J.; Zimmermann M.; Zoche M.; Zuend G.; Levesque M.P.; Dummer R.; Moch H.; Koelzer V.H.. Laboratory Investigation. 2021.Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years.
Pedrazzani C; Ming C; Bürki N; Caiata-Zufferey M; Chappuis PO; Duquette D; Heinimann K; Heinzelmann-Schwarz V; Graffeo-Galbiati R; Merajver SD; Milliron KJ; Monnerat C; Pagani O; Rabaglio M; Katapodi MC. Cancers. 2021.High-grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer.
Jacob F; Marchetti RL; Kind AB; Russell K; Schoetzau A; Heinzelmann-Schwarz VA. Molecular oncology. 2021.Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform.
Koelzer VH; Herzig P; Zlobec I; Heinzelmann V; Lardinois D; Walseng E; Rader C; Mertz KD; Zippelius A; Thommen DS. Immuno-oncology technology. 2021.L1CAM is not a reliable predictor for lymph node metastases in endometrial cancer, but L1CAM positive patients benefit from radiotherapy.
Zeiter D; Vlajnic T; Schötzau A; Heinzelmann-Schwarz V; Montavon C. Journal of Cancer. 2021.Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity.
Natoli M; Herzig P; Pishali Bejestani E; Buchi M; Ritschard R; Lloyd GK; Mohanlal R; Tonra JR; Huang L; Heinzelmann V; Trüb M; Zippelius A; Kashyap AS. Frontiers in oncology. 2021.The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support
Irmisch A.; Bonilla X.; Chevrier S.; Lehmann K.-V.; Singer F.; Toussaint N.C.; Esposito C.; Mena J.; Milani E.S.; Casanova R.; Stekhoven D.J.; Wegmann R.; Jacob F.; Sobottka B.; Goetze S.; Kuipers J.; Sarabia del Castillo J.; Prummer M.; Tuncel M.A.; Menzel U.; Jacobs A.; Engler S.; Sivapatham S.; Frei A.L.; Gut G.; Ficek J.; Miglino N.; Ak M.; Al-Quaddoomi F.S.; Albinus J.; Alborelli I.; Andani S.; Attinger P.-O.; Baumhoer D.; Beck-Schimmer B.; Bernasconi L.; Bertolini A.; Chicherova N.; D'Costa M.; Danenberg E.; Davidson N.; Dragan M.-A.; Erkens M.; Eschbach K.; Fedier A.; Ferreira P.; Frey B.; Grob L.; Gunther D.; Haberecker M.; Haeuptle P.; Herter S.; Holtackers R.; Huesser T.; Jaeger T.M.; Jahn K.; James A.R.; Jermann P.M.; Kahles A.; Kahraman A.; Kuebler W.; Kunze C.P.; Kurzeder C.; Lugert S.; Maass G.; Markolin P.; Metzler J.M.; Muenst S.; Murri R.; Ng C.K.Y.; Nicolet S.; Nowak M.; Pedrioli P.G.A.; Piscuoglio S.; Ritter M.; Rommel C.; Rosano-Gonzalez M.L.; Santacroce N.; Schlenker R.; Schwalie P.C.; Schwan S.; Schar T.; Senti G.; Sreedharan V.T.; Stark S.; Thomas T.M.; Tosevski V.; Tusup M.; Van Drogen A.; Vetter M.; Vlajnic T.; Weber S.; Weber W.P.; Weller M.; Wendt F.; Wey N.; Wildschut M.H.E.; Yu S.; Ziegler J.; Zimmermann M.; Zoche M.; Zuend G.; Aebersold R.; Bacac M.; Beerenwinkel N.; Beisel C.; Bodenmiller B.; Dummer R.; Heinzelmann-Schwarz V.; Koelzer V.H.; Manz M.G.; Moch H.; Pelkmans L.; Snijder B.; Theocharides A.P.A.; Tolnay M.; Wicki A.; Wollscheid B.; Ratsch G.; Levesque M.P.. Cancer Cell. 2021.Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.
Kim S; Aceti M; Baroutsou V; Bürki N; Caiata-Zufferey M; Cattaneo M; Chappuis PO; Ciorba FM; Graffeo-Galbiati R; Heinzelmann-Schwarz V; Jeong J; Jung MM; Kim SW; Kim J; Lim MC; Ming C; Monnerat C; Park HS; Park SH; Pedrazzani CA; Rabaglio M; Ryu JM; Saccilotto R; Wieser S; Zürrer-Härdi U; Katapodi MC. JMIR research protocols. 2021.Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM. Gynecologic oncology. 2020.Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis.
Huang YL; Liang CY; Ritz D; Coelho R; Septiadi D; Estermann M; Cumin C; Rimmer N; Schötzau A; Núñez López M; Fedier A; Konantz M; Vlajnic T; Calabrese D; Lengerke C; David L; Rothen-Rutishauser B; Jacob F; Heinzelmann-Schwarz V. eLife. 2020.Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Trüb M; Uhlenbrock F; Claus C; Herzig P; Thelen M; Karanikas V; Bacac M; Amann M; Albrecht R; Ferrara-Koller C; Thommen D; Rothschield S; Savic Prince S; Mertz KD; Cathomas G; Rosenberg R; Heinzelmann-Schwarz V; Wiese M; Lardinois D; Umana P; Klein C; Laubli H; Kashyap AS; Zippelius A. Journal for ImmunoTherapy of Cancer. 2020.L1 Cell Adhesion Molecule Confers Radioresistance to Ovarian Cancer and Defines a New Cancer Stem Cell Population.
Terraneo N; Jacob F; Peitzsch C; Dubrovska A; Krudewig C; Huang YL; Heinzelmann-Schwarz V; Schibli R; Béhé M; Grünberg J. Cancers. 2020.Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion.
Estermann M; Huang YL; Septiadi D; Ritz D; Liang CY; Jacob F; Drasler B; Petri-Fink A; Heinzelmann-Schwarz V; Rothen-Rutishauser B. PLoS One. 2020.Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation.
Coelho R; Ricardo S; Amaral AL; Huang YL; Nunes M; Neves JP; Mendes N; López MN; Bartosch C; Ferreira V; Portugal R; Lopes JM; Almeida R; Heinzelmann-Schwarz V; Jacob F; David L. Oncogenesis. 2020.Reply to comment on: Wiser et al. Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data. Swiss Med Wkly.2018;148:w14647.
Wieser S; Schmidt M; Kind AB; Heinzelmann-Schwarz VA. . 2020.Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
Heinzelmann-Schwarz V; Kind AB; Vetter M; Russell K; Omar S; Schoetzau A; Hoeck K; Fink D; Friedlander ML; Hacker NF. Journal of cancer research and clinical oncology. 2020.A forgotten disease: Pelvic congestion syndrome as a cause of chronic lower abdominal pain.
Jurga-Karwacka A; Karwacki GM; Schoetzau A; Zech CJ; Heinzelmann-Schwarz V; Schwab FD. PLoS One. 2019.A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.
Hüttenhain R; Choi M; Martin de la Fuente L; Oehl K; Chang CY; Zimmermann AK; Malander S; Olsson H; Surinova S; Clough T; Heinzelmann-Schwarz V; Wild PJ; Dinulescu DM; Niméus E; Vitek O; Aebersold R. Molecular & cellular proteomics : MCP. 2019.Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding.
Gkountela S; Castro-Giner F; Szczerba BM; Vetter M; Landin J; Scherrer R; Krol I; Scheidmann MC; Beisel C; Stirnimann CU; Kurzeder C; Heinzelmann-Schwarz V; Rochlitz C; Weber WP; Aceto N. Cell. 2019.Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
Labidi-Galy SI; de La Motte Rouge T; Derbel O; Wolfer A; Kalbacher E; Olivier T; Combes JD; Heimgartner-Hu K; Tredan O; Guevara H; Heudel PE; Reverdy T; Bazan F; Heinzelmann-Schwarz V; Fehr M; de Castelbajac V; Vaflard P; Crivelli L; Bonadona V; Viassolo V; Buisson A; Golmard L; Rodrigues M; Ray-Coquard I. Gynecologic oncology. 2019.Fibrin-thrombin sealant does not reduce lymphocele formation in patients with inguinofemoral lymphadenectomy for vulvar cancer.
Saner FA; Schötzau A; Mackay G; Heinzelmann-Schwarz V; Montavon Sartorius C. Cancer Management and Research. 2019.Neutrophils escort circulating tumour cells to enable cell cycle progression.
Szczerba BM; Castro-Giner F; Vetter M; Krol I; Gkountela S; Landin J; Scheidmann MC; Donato C; Scherrer R; Singer J; Beisel C; Kurzeder C; Heinzelmann-Schwarz V; Rochlitz C; Weber WP; Beerenwinkel N; Aceto N. Nature. 2019.Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C. Journal for ImmunoTherapy of Cancer. 2019.Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A. Journal of cancer research and clinical oncology. 2019.Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Claus C; Ferrara C; Xu W; Sam J; Lang S; Uhlenbrock F; Albrecht R; Herter S; Schlenker R; Hüsser T; Diggelmann S; Challier J; Mössner E; Hosse RJ; Hofer T; Brünker P; Joseph C; Benz J; Ringler P; Stahlberg H; Lauer M; Perro M; Chen S; Küttel C; Bhavani Mohan PL; Nicolini V; Birk MC; Ongaro A; Prince C; Gianotti R; Dugan G; Whitlow CT; Solingapuram Sai KK; Caudell DL; Burgos-Rodriguez AG; Cline JM; Hettich M; Ceppi M; Giusti AM; Crameri F; Driessen W; Morcos PN; Freimoser-Grundschober A; Levitsky V; Amann M; Grau-Richards S; von Hirschheydt T; Tournaviti S; Mølhøj M; Fauti T; Heinzelmann-Schwarz V; Teichgräber V; Colombetti S; Bacac M; Zippelius A; Klein C; Umaña P. Science Translational Medicine. 2019.ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.
Montavon Sartorius C; Schoetzau A; Kettelhack H; Fink D; Hacker NF; Fedier A; Jacob F; Heinzelmann-Schwarz V. PLoS One. 2018.Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop.
Nikolaidis C; Ming C; Pedrazzani C; van der Horst T; Kaiser-Grolimund A; Ademi Z; Bührer-Landolt R; Bürki N; Caiata-Zufferey M; Champion V; Chappuis PO; Kohler C; Erlanger TE; Graffeo R; Hampel H; Heinimann K; Heinzelmann-Schwarz V; Kurzeder C; Monnerat C; Northouse LL; Pagani O; Probst-Hensch N; Rabaglio M; Schoenau E; Sijbrands EJG; Taborelli M; Urech C; Viassolo V; Wieser S; Katapodi MC; for the CASCADE Consortium. Public health genomics. 2018.Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO Switzerland.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J. Archives of gynecology and obstetrics. 2018.Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.
Vetter M; Landin J; Szczerba BM; Castro-Giner F; Gkountela S; Donato C; Krol I; Scherrer R; Balmelli C; Malinovska A; Zippelius A; Kurzeder C; Heinzelmann-Schwarz V; Weber WP; Rochlitz C; Aceto N. BREAST CANCER RESEARCH. 2018.Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers.
Montavon C; Mirza U; Fedier A; Schoetzau A; Zanetti Dällenbach R; Heinzelmann-Schwarz V. Experimental and Therapeutic Medicine. 2018.Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers.
Montavon Sartorius C; Mirza U; Schötzau A; Mackay G; Fink D; Hacker NF; Heinzelmann-Schwarz V. Cancer Management and Research. 2018.Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M. Gynecologic oncology. 2018.Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data.
Wieser S; Schmidt M; Kind AB; Heinzelmann-Schwarz VA. Swiss medical weekly. 2018.Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H. Journal of Clinical Investigation. 2018.The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J. Archives of gynecology and obstetrics. 2018.Transition of Mesenchymal and Epithelial Cancer Cells Depends on α1-4 Galactosyltransferase-Mediated Glycosphingolipids.
Jacob F; Alam S; Konantz M; Liang CY; Kohler RS; Everest-Dass AV; Huang YL; Rimmer N; Fedier A; Schötzau A; Lopez MN; Packer NH; Lengerke C; Heinzelmann-Schwarz V. Cancer research. 2018.Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
Katapodi MC; Viassolo V; Caiata-Zufferey M; Nikolaidis C; Bührer-Landolt R; Buerki N; Graffeo R; Horváth HC; Kurzeder C; Rabaglio M; Scharfe M; Urech C; Erlanger TE; Probst-Hensch N; Heinimann K; Heinzelmann-Schwarz V; Pagani O; Chappuis PO. JMIR research protocols. 2017.Intra-, peri- and postoperative complications in pelvic organ prolapse surgery in elderly women
Kornig, M. P.; Bruhlmann, E.; Heinzelmann-Schwarz, V; Gunthert, A.; Christmann, C.. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY. 2017.MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V. Gynecologic oncology. 2017.Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients.
Pochechueva T; Alam S; Schötzau A; Chinarev A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V. Journal of Ovarian Research. 2017.Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study.
Magaton IM; Tzankov A; Krasniqi F; Rottenburger C; Zanetti-Daellenbach R; Grendelmeier P; Heinzelmann-Schwarz V; Mayr M; Schwab FD. Case Rep Oncol (ONLINE-AUSGABE). 2017.Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma
Anugraham, Merrina; Jacob, Francis; Everest-Dass, Arun V.; Schoetzau, Andreas; Nixdorf, Sheri; Hacker, Neville F.; Fink, Daniel; Heinzelmann-Schwarz, Viola; Packer, Nicolle H.. Molecular oncology. 2017.Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
Pochechueva T; Chinarev A; Schoetzau A; Fedier A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V. PLoS One. 2016.Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients.
Kohler RS; Anugraham M; López MN; Xiao C; Schoetzau A; Hettich T; Schlotterbeck G; Fedier A; Jacob F; Heinzelmann-Schwarz V. Oncotarget. 2016.Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.
Schreiner J; Thommen DS; Herzig P; Bacac M; Klein C; Roller A; Belousov A; Levitsky V; Savic S; Moersig W; Uhlenbrock F; Heinzelmann-Schwarz VA; Umana P; Pisa P; von Bergwelt-Baildon M; Lardinois D; Müller P; Karanikas V; Zippelius A. Oncoimmunology. 2016.Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.
Schreiner J; Thommen DS; Herzig P; Bacac M; Klein C; Roller A; Belousov A; Levitsky V; Savic S; Moersig W; Uhlenbrock F; Heinzelmann-Schwarz VA; Umana P; Pisa P; von Bergwelt-Baildon M; Lardinois D; Müller P; Karanikas V; Zippelius A. Oncoimmunology. 2016.HIGH-GRADE SEROUS OVARIAN AND PERITONEAL CANCERS DISPLAY DISTINCT GENETIC AND POST-TRANSLATIONAL SIGNATURES -A CRITERION TO TREAT THEM DIFFERENTLY?
Jacob, F.; Anugraham, M.; Schotzau, A.; Everest-Dass, A.; Bovin, N.; Huflejt, M. E.; Fedier, A.; Hacker, N.; Fink, D.; Packer, N.; Heinzelmann-Schwarz, V.. International Journal of Gynecological Cancer. 2016.Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting
Manegold-Brauer G.; Buechel J.; Knipprath-Meszaros A.; Schoetzau A.; Hacker N.F.; Tercanli S.; Lapaire O.; Heinzelmann-Schwarz V.. International Journal of Gynecological Cancer. 2016.Long-term quality of life, satisfaction, pelvic floor symptoms and regret after colpocleisis.
Katsara A; Wight E; Heinzelmann-Schwarz V; Kavvadias T. Archives of gynecology and obstetrics. 2016.LOW MGAT3 EXPRESSION IDENTIFIES LONG-TERM SURVIVORS WITH HIGH GRADE SEROUS OVARIAN CANCER
Kohler, R. S.; Anugraham, M.; Lopez, M. N. Nunez; Schotzau, A.; Hettich, T.; Schlotterbeck, G.; Fedier, A.; Jacob, F.; Heinzelmann-Schwarz, V.. International Journal of Gynecological Cancer. 2016.Molecular characterization and comparison of epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PCC)
Knipprath, A. M.; Arguello, D.; Russell, K.; Voss, A.; Heinzelmann-Schwarz, V.. Annals of oncology : official journal of the European Society for Medical Oncology. 2016.Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells.
Decollogne S; Joshi S; Chung SA; Luk PP; Yeo RX; Nixdorf S; Fedier A; Heinzelmann-Schwarz V; Hogg PJ; Dilda PJ. Gynecologic oncology. 2015.Comment on the letter: the mass cannot be classified as malignant.
Manegold-Brauer G; Heinzelmann-Schwarz V. Archives of gynecology and obstetrics. 2015.Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.
Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C. Oncotarget. 2015.A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker.
Heinzelmann-Schwarz VA; Nixdorf S; Valadan M; Diczbalis M; Olivier J; Otton G; Fedier A; Hacker NF; Scurry JP. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2014.Antibody-based immunotherapy for ovarian cancer: where are we at?
Tse BW; Collins A; Oehler MK; Zippelius A; Heinzelmann-Schwarz VA. Annals of oncology : official journal of the European Society for Medical Oncology. 2014.Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.
Jacob F; Hitchins MP; Fedier A; Brennan K; Nixdorf S; Hacker NF; Ward R; Heinzelmann-Schwarz VA. BMC MOLECULAR BIOLOGY. 2014.Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer.
Schwab FD; Bürki N; Huang DJ; Heinzelmann-Schwarz V; Schmid SM; Vetter M; Schötzau A; Güth U. Familial cancer. 2014.Management of human papillomavirus-related gynecological malignancies.
Heinzelmann-Schwarz VA; Kind AB; Jacob F. Current problems in dermatology. 2014.Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.
Müller P; Martin K; Theurich S; Schreiner J; Savic S; Terszowski G; Lardinois D; Heinzelmann-Schwarz VA; Schlaak M; Kvasnicka HM; Spagnoli G; Dirnhofer S; Speiser DE; von Bergwelt-Baildon M; Zippelius A. Cancer immunology research. 2014.PEGylation of microbead surfaces reduces unspecific antibody binding in glycan-based suspension array.
Pochechueva T; Chinarev A; Bovin N; Fedier A; Jacob F; Heinzelmann-Schwarz V. Journal of Immunological Methods. 2014.Reliable in vitro studies require appropriate ovarian cancer cell lines.
Jacob F; Nixdorf S; Hacker NF; Heinzelmann-Schwarz VA. Journal of Ovarian Research. 2014.Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status.
Anugraham M; Jacob F; Nixdorf S; Everest-Dass AV; Heinzelmann-Schwarz V; Packer NH. Molecular & cellular proteomics : MCP. 2014.The glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration.
Jacob F; Anugraham M; Pochechueva T; Tse BW; Alam S; Guertler R; Bovin NV; Fedier A; Hacker NF; Huflejt ME; Packer N; Heinzelmann-Schwarz VA. British journal of cancer. 2014.The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.
Martin K; Müller P; Schreiner J; Prince SS; Lardinois D; Heinzelmann-Schwarz VA; Thommen DS; Zippelius A. Cancer immunology, immunotherapy : CII. 2014.The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer.
Ford CE; Punnia-Moorthy G; Henry CE; Llamosas E; Nixdorf S; Olivier J; Caduff R; Ward RL; Heinzelmann-Schwarz V. Gynecologic oncology. 2014.The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: Distinction from other methods of diagnostic imaging
Manegold-Brauer G.; Bellin A.K.; Tercanli S.; Lapaire O.; Heinzelmann-Schwarz V.. Archives of gynecology and obstetrics. 2014.Bilateral breast masses with a rare etiology.
Thieringer F; Sartorius G; Kalf K; Heinzelmann V; Vetter M. Case reports in oncological medicine. 2013.Careful Selection of Reference Genes Is Required for Reliable Performance of RT-qPCR in Human Normal and Cancer Cell Lines
Jacob, Francis; Guertler, Rea; Naim, Stephanie; Nixdorf, Sheri; Fedier, Andre; Hacker, Neville F.; Heinzelmann-Schwarz, Viola. PLoS One. 2013.Meta-analysis of microarray data identifies gas6 expression as an independent predictor of poor survival in ovarian cancer
Buehler M.; Tse B.; Leboucq A.; Jacob F.; Caduff R.; Fink D.; Goldstein D.R.; Heinzelmann-Schwarz V.. BioMed research international. 2013.Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease.
Güth U; Vetter M; Huang DJ; Heinzelmann-Schwarz V. Annals of oncology : official journal of the European Society for Medical Oncology. 2013.The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.
Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL. PLoS One. 2013.Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.
Jacob F; Ukegjini K; Nixdorf S; Ford CE; Olivier J; Caduff R; Scurry JP; Guertler R; Hornung D; Mueller R; Fink DA; Hacker NF; Heinzelmann-Schwarz VA. PLoS One. 2012.LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
Cowin PA; George J; Fereday S; Loehrer E; Van Loo P; Cullinane C; Etemadmoghadam D; Ftouni S; Galletta L; Anglesio MS; Hendley J; Bowes L; Sheppard KE; Christie EL; Pearson RB; Harnett PR; Heinzelmann-Schwarz V; Friedlander M; McNally O; Quinn M; Campbell P; deFazio A; Bowtell DD; Australian Ovarian Cancer Study. Cancer research. 2012.Protein significance analysis in selected reaction monitoring (SRM) measurements.
Chang CY; Picotti P; Hüttenhain R; Heinzelmann-Schwarz V; Jovanovic M; Aebersold R; Vitek O. Molecular & cellular proteomics : MCP. 2012.Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array.
Jacob F; Goldstein DR; Bovin NV; Pochechueva T; Spengler M; Caduff R; Fink D; Vuskovic MI; Huflejt ME; Heinzelmann-Schwarz V. International Journal of Cancer. 2012.Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.
Pochechueva T; Jacob F; Fedier A; Heinzelmann-Schwarz V. Metabolites. 2012.[Epithelial ovarian cancer - a change of paradigm].
Heinzelmann-Schwarz V. Therapeutische Umschau. 2011.Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies.
Pochechueva T; Jacob F; Goldstein DR; Huflejt ME; Chinarev A; Caduff R; Fink D; Hacker N; Bovin NV; Heinzelmann-Schwarz V. Glycoconjugate journal. 2011.Multiplex suspension array for human anti-carbohydrate antibody profiling.
Pochechueva T; Chinarev A; Spengler M; Korchagina E; Heinzelmann-Schwarz V; Bovin N; Rieben R. ANALYST. 2011.No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
Jacob, Francis; Meier, Mara; Caduff, Rosmarie; Goldstein, Darlene; Pochechueva, Tatiana; Hacker, Neville; Fink, Daniel; Heinzelmann-Schwarz, Viola. Gynecologic oncology. 2011.URI is an oncogene amplified in ovarian cancer cells and is required for their survival.
Theurillat JP; Metzler SC; Henzi N; Djouder N; Helbling M; Zimmermann AK; Jacob F; Soltermann A; Caduff R; Heinzelmann-Schwarz V; Moch H; Krek W. Cancer Cell. 2011.Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs.
Jacob F; Goldstein DR; Fink D; Heinzelmann-Schwarz V. Biomarkers in Medicine. 2009.The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
O'Brien PM; Davies MJ; Scurry JP; Smith AN; Barton CA; Henderson MJ; Saunders DN; Gloss BS; Patterson KI; Clancy JL; Heinzelmann-Schwarz VA; Murali R; Scolyer RA; Zeng Y; Williams ED; Scurr L; Defazio A; Quinn DI; Watts CK; Hacker NF; Henshall SM; Sutherland RL. British journal of cancer. 2008.Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries.
Heinzelmann-Schwarz VA; Scolyer RA; Scurry JP; Smith AN; Gardiner-Garden M; Biankin AV; Baron-Hay S; Scott C; Ward RL; Fink D; Hacker NF; Sutherland RL; O'Brien PM. Journal of clinical pathology. 2007.A distinct molecular profile associated with mucinous epithelial ovarian cancer.
Heinzelmann-Schwarz VA; Gardiner-Garden M; Henshall SM; Scurry JP; Scolyer RA; Smith AN; Bali A; Vanden Bergh P; Baron-Hay S; Scott C; Fink D; Hacker NF; Sutherland RL; O'Brien PM. British journal of cancer. 2006.Overexpression of the cell adhesion molecules DDR1, claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer
Heinzelmann-Schwarz, VA; Gardiner-Garden, M; Henshall, SM; Scurry, J; Scolyer, RA; Davies, MJ; Heinzelmann, M; Kalish, LH; Bali, A; Kench, JG; Edwards, LS; Vanden Bergh, PM; Hacker, NF; Sutherland, RL; O'Brien, PM. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004.Role of p53 and ATM in photodynamic therapy-induced apoptosis.
Heinzelmann-Schwarz V; Fedier A; Hornung R; Walt H; Haller U; Fink D. Lasers in Surgery and Medicine. 2003.